Nyxoah SA , a leading medical technology company specializing in innovative solutions for Obstructive Sleep Apnea (OSA), has forged a significant partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation (AAO-HNSF). This collaboration marks Nyxoah as the first medical device company to attain the status of Corporate Champion within the ENTerprise Circle of the AAO-HNSF.

The AAO-HNSF is dedicated to ensuring access to high-quality otolaryngology-head and neck services, aligning with Nyxoah's mission to advance OSA treatment. Through joint efforts with partners like Nyxoah, the AAO-HNSF Advocacy team works diligently to address coverage policies that may impede patient access to care.

The partnership aims to improve patient access to innovative OSA treatments through various initiatives. These include navigating prior authorization requirements with CMS and Private Payers, engaging with regulatory bodies such as the FDA and AMA CPT to broaden care accessibility, and advocating for streamlined processes for new bilateral hypoglossal nerve stimulation (HGNS) therapy. These efforts involve developing clinical guidelines endorsed by CMS and commercial insurance payers.

As HGNS gains prominence in OSA treatment, ENT specialists play a crucial role. Nyxoah's Genio represents a cutting-edge advancement in HGNS technology, and the AAO-HNSF is enthusiastic about collaborating with Nyxoah to ensure broad access to this transformative system for patients nationwide.

Nyxoah's CEO emphasized the shared commitment to prioritizing patient well-being and facilitating access to HGNS therapy, underscoring their dedication to advancing patient-centered care.

Source: globenewswire.com

 

 

 

Report Abuse